Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Notebook: A Smooth Succession At Roche, EMA’s New Leadership Team, A Medicine Bank In Greece, Atorvastatin Price Drop In Ireland

Executive Summary

Lufthansa's Christoph Franz will become Roche’s chairman next year; more restructuring details emerge from the European Medicines Agency; pharma companies donate medicines in Greece; Ireland names preferred medicines and aims to cut atorvastatin price.

You may also be interested in...



EMA’s Heralded Revamp May Be Hampered By Tight Budget And Staffing

The EMA has announced a major restructuring plan to better aid its stakeholders, but tight staffing levels and budget stagnation could hamper the effort.

German Drug Report Could Mean More Pressure On Pharma Revenues

The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.

European Notebook: AstraZeneca Snuggles Up To Potential Partners In New Cambridge HQ, Viagra Patents Expire In Europe

AstraZeneca's new HQ is to cornerstone a growing U.K. cluster of clinical and research assets; the EU and U.S. start talks on what could be the world's largest free trade agreement; Viagra patent expiry provides a lift for European generic companies; European wholesalers support the liquidity of European health care markets; new pricing system for generics in Ireland.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel